Vcutta ya yakm iini CLA yapar
KEY FINDINGS BAR (8 stat cards) STAT 1: $150B - projected global category size by 2030 STAT 2: ~58% - of total category AI citation share captured by six pharma brands STAT 3: 2 - companies (Novo Nordisk and Eli Lilly) own nearly 100% of GLP-1 citations STAT 4: ~13% - AI Overview trigger rate on health queries, highest of any consumer category STAT 5: 60-70% - share of "best diet app" AI answers citing MyFitnessPal first STAT 6: 200M+ - registered MyFitnessPal user base, the informational moat behind its citation lock STAT 7: 60+ - consumer prompts tracked across ChatGPT, Claude, Perplexity, and Google AI Overviews to build the index STAT 8: 25 - brands ranked, with the remaining ~11% citation share split across ranks 16-25 and unranked brands THE TOP 15 BY AI CITATION SHARE Estimated share of citations across 60+ weight-loss-related consumer prompts run through ChatGPT, Claude, Perplexity, and Google AI Overviews, Q1 2026
For people with type 2 diabetes, GLP-1 medications may also improve blood sugar control
[4] When Medicare Part D or Medicaid does cover tirzepatide, your monthly cost can range anywhere from $0 to a few hundred dollars, depending on your plans tier, deductible, and pharmacy network
